According to Onconova Therapeutics's latest financial reports and stock price the company's current Operating Margin is -8,391.15%. At the end of 2021 the company had an Operating Margin of -7,299.12%.
Year | Operating Margin | Change |
---|---|---|
2021 | -7,299.12% | -32.54% |
2020 | -10,819.48% | 988.48% |
2019 | -994.00% | -47.57% |
2018 | -1,895.93% | -42.03% |
2017 | -3,270.27% | 665.17% |
2016 | -427.39% | 104.25% |
2015 | -209.25% | -97.38% |
2014 | -7,971.75% | 509.97% |
2013 | -1,306.90% | 2733.54% |
2012 | -46.12% | -97.39% |
2011 | -1,766.98% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() | -109.76% | -98.69% | ๐บ๐ธ USA |
![]() | -4.31% | -99.95% | ๐บ๐ธ USA |
![]() | 1.18% | -100.01% | ๐บ๐ธ USA |
![]() | -172.37% | -97.95% | ๐บ๐ธ USA |
![]() | N/A | N/A | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.